Press Releases
// Aug 04, 2022
ElevateBio Announces the Formation of a New Company with George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies
// Jun 02, 2022
ElevateBio Announces Jill M. Mooney, Ph.D., Joins as Senior Vice President of Research and Development
// May 04, 2022
ElevateBio Announces Presentation on Lentiviral Vector Platform at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
// Jan 06, 2022
ElevateBio to Present at the 40th Annual J.P. Morgan Healthcare Conference
// Nov 15, 2021
ElevateBio Announces Issuance of U.S. Patent Providing Protection for RNA-Guided Nucleases Identified through its Life Edit Gene Editing Platform
// Oct 27, 2021
ElevateBio Supercharges Gene Editing and Therapeutic Product Development Capabilities Through Acquisition of Life Edit Therapeutics
// Jun 29, 2021
Boston Children’s Hospital and ElevateBio Announce Five-Year Cell and Gene Therapy Collaboration
// Jun 10, 2021
ElevateBio Announces Margo Roberts, Ph.D. Joins as Scientific Advisor for Company’s Immunotherapy Platform Expansion
// Apr 27, 2021
ElevateBio’s BaseCamp Selected as the 2021 Facility of the Year Award Category Winner for Operational Excellence by the International Society for Pharmaceutical Engineering
// Mar 18, 2021
ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell Research Board of Directors
// Mar 15, 2021
ElevateBio Scales Disruptive Cell and Gene Therapy Business Model with $525 Million Series C Financing
// Jan 19, 2021
